Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Комбинированная антитромбоцитарная терапия у больных, перенесших обострение ишемической болезни сердца – современные возможности выбора
Типтева1 Т.А., Затейщиков1,2,3 Д.А. Комбинированная антитромбоцитарная терапия у больных, перенесших обострение ишемической болезни сердца – современные возможности выбора. Consilium Medicum. 2013; 15 (5): 83–86.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Yusuf S, Zhao F, Mehta SR et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial I: Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med 2001; 345 (7): 494–502.
2. Mehta SR, Yusuf S, Peters RJ et al: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The pci-cure study. Lancet 2001; 358 (9281): 527–33.
3. Linden J. Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection. Ann Rev Pharmacol Toxicol 2001; 41: 775–87.
4. Ramaraj R, Movahed MR, Hashemzadeh M. Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome. J Int Cardiology 2011; 24 (3): 199–207.
5. Wang W, Wang H, Wang X, Zeng C. A transition of p2y12 antagonists for acute coronary syndrome: Benefits, risks and costs. J Thromb Thrombolysis 2013; 1–5.
6. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11): 1045–57.
7. James SK, Roe MT, Cannon CP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: Substudy from prospective randomised platelet inhibition and patient outcomes (plato) trial. BMJ 2011; 342: d3527.
8. Held C, Asenblad N, Bassand JP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: Results from the plato (platelet inhibition and patient outcomes) trial. J Am Coll Cardiol 2011; 57 (6): 672–84.
9. Tantry US, Bliden KP, Wei C et al. First analysis of the relation between cyp2c19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: The onset/offset and respond genotype studies. Circ Cardiovascular Genetics 2010; 3 (6): 556–66.
10. Crouch MA, Colucci VJ, Howard PA, Spinler SA. P2y(1)(2) receptor inhibitors: Integrating ticagrelor into the management of acute coronary syndrome. Ann Pharmacother 2011; 45 (9): 1151–6.
11. Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol 2013; 69 (3): 477–87.
12. Becker RC, Bassand JP, Budaj A et al. Bleeding complications with the p2y12 receptor antagonists clopidogrel and ticagrelor in the platelet inhibition and patient outcomes (plato) trial. Eur Heart J 2011; 32 (23): 2933–44.
13. Mahaffey KW, Wojdyla DM, Carroll K et al: Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (plato) trial. Circulation 2011; 124 (5): 544–54.
14. Butler K, Maya J, Teng R. Effect of ticagrelor on pulmonary function in healthy elderly volunteers and asthma or chronic obstructive pulmonary disease patients. Curr Med Res Opin 2013; 29 (5): 569–77.
15. Grzesk G, Kozinski M, Navarese EP et al. Ticagrelor, but not clopidogrel and prasugrel, prevents adp-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats. Thromb Res 2012; 130 (1): 65–9.
16. Patil SB, Jackman LE, Francis SE et al. Ticagrelor effectively and reversibly blocks murine platelet p2y12-mediated thrombosis and demonstrates a requirement for sustained p2y12 inhibition to prevent subsequent neointima. Arteriosclerosis, thrombosis, and vascular biology 2010; 30 (12): 2385–91.
17. Torngren K, Ohman J, Salmi H et al. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology 2013; 124 (4): 252–8.
2. Mehta SR, Yusuf S, Peters RJ et al: Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: The pci-cure study. Lancet 2001; 358 (9281): 527–33.
3. Linden J. Molecular approach to adenosine receptors: Receptor-mediated mechanisms of tissue protection. Ann Rev Pharmacol Toxicol 2001; 41: 775–87.
4. Ramaraj R, Movahed MR, Hashemzadeh M. Novel antiplatelet agent ticagrelor in the management of acute coronary syndrome. J Int Cardiology 2011; 24 (3): 199–207.
5. Wang W, Wang H, Wang X, Zeng C. A transition of p2y12 antagonists for acute coronary syndrome: Benefits, risks and costs. J Thromb Thrombolysis 2013; 1–5.
6. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11): 1045–57.
7. James SK, Roe MT, Cannon CP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: Substudy from prospective randomised platelet inhibition and patient outcomes (plato) trial. BMJ 2011; 342: d3527.
8. Held C, Asenblad N, Bassand JP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: Results from the plato (platelet inhibition and patient outcomes) trial. J Am Coll Cardiol 2011; 57 (6): 672–84.
9. Tantry US, Bliden KP, Wei C et al. First analysis of the relation between cyp2c19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: The onset/offset and respond genotype studies. Circ Cardiovascular Genetics 2010; 3 (6): 556–66.
10. Crouch MA, Colucci VJ, Howard PA, Spinler SA. P2y(1)(2) receptor inhibitors: Integrating ticagrelor into the management of acute coronary syndrome. Ann Pharmacother 2011; 45 (9): 1151–6.
11. Teng R, Mitchell PD, Butler KA. Pharmacokinetic interaction studies of co-administration of ticagrelor and atorvastatin or simvastatin in healthy volunteers. Eur J Clin Pharmacol 2013; 69 (3): 477–87.
12. Becker RC, Bassand JP, Budaj A et al. Bleeding complications with the p2y12 receptor antagonists clopidogrel and ticagrelor in the platelet inhibition and patient outcomes (plato) trial. Eur Heart J 2011; 32 (23): 2933–44.
13. Mahaffey KW, Wojdyla DM, Carroll K et al: Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (plato) trial. Circulation 2011; 124 (5): 544–54.
14. Butler K, Maya J, Teng R. Effect of ticagrelor on pulmonary function in healthy elderly volunteers and asthma or chronic obstructive pulmonary disease patients. Curr Med Res Opin 2013; 29 (5): 569–77.
15. Grzesk G, Kozinski M, Navarese EP et al. Ticagrelor, but not clopidogrel and prasugrel, prevents adp-induced vascular smooth muscle cell contraction: A placebo-controlled study in rats. Thromb Res 2012; 130 (1): 65–9.
16. Patil SB, Jackman LE, Francis SE et al. Ticagrelor effectively and reversibly blocks murine platelet p2y12-mediated thrombosis and demonstrates a requirement for sustained p2y12 inhibition to prevent subsequent neointima. Arteriosclerosis, thrombosis, and vascular biology 2010; 30 (12): 2385–91.
17. Torngren K, Ohman J, Salmi H et al. Ticagrelor improves peripheral arterial function in patients with a previous acute coronary syndrome. Cardiology 2013; 124 (4): 252–8.
Авторы
Т.А.Типтева1, Д.А.Затейщиков1,2,3
1. ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ;
2. ФГБУ ФНКЦ специализированных видов медицинской помощи и медицинских технологий ФМБА РФ;
3. ГБУЗ Городская клиническая больница №51 ДЗМ, Москва
1. ФГБУ Учебно-научный медицинский центр Управления делами Президента РФ;
2. ФГБУ ФНКЦ специализированных видов медицинской помощи и медицинских технологий ФМБА РФ;
3. ГБУЗ Городская клиническая больница №51 ДЗМ, Москва
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.